Incyte Corporation

NasdaqGS:INCY 주식 보고서

시가총액: US$13.8b

Incyte 미래 성장

Future 기준 확인 5/6

Incyte (는) 각각 연간 46.5% 및 9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 46% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 24.7% 로 예상됩니다.

주요 정보

46.5%

수익 성장률

46.0%

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률9.0%
향후 자기자본 수익률24.7%
애널리스트 커버리지

Good

마지막 업데이트25 Nov 2024

최근 미래 성장 업데이트

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Feb 02
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Oct 31
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27
With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

수익 및 매출 성장 예측

NasdaqGS:INCY - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20265,1301,2751,5371,57718
12/31/20254,6359721,2501,14422
12/31/20244,2047919333122
9/30/20244,0763217102N/A
6/30/20243,85797-140-61N/A
3/31/20243,768745791821N/A
12/31/20233,696598449496N/A
9/30/20233,609425566632N/A
6/30/20233,513366698781N/A
3/31/20233,470324561649N/A
12/31/20223,395341892970N/A
9/30/20223,331876711802N/A
6/30/20223,320945665760N/A
3/31/20223,115933609759N/A
12/31/20212,986949568749N/A
9/30/20212,913535543741N/A
6/30/20212,721338450668N/A
3/31/20212,703478569765N/A
12/31/20202,667-296-312-125N/A
9/30/20202,457-335-266-100N/A
6/30/20202,388-191-108-12N/A
3/31/20202,229-376-227-128N/A
12/31/20192,159447633711N/A
9/30/20192,108405589663N/A
6/30/20192,006306476592N/A
3/31/20191,997253392471N/A
12/31/20181,882109263336N/A
9/30/20181,798-10990163N/A
6/30/20181,729-102N/A17N/A
3/31/20181,534-167N/A101N/A
12/31/20171,536-313N/A-93N/A
9/30/20171,419-155N/A91N/A
6/30/20171,306-154N/A133N/A
3/31/20171,226-107N/A34N/A
12/31/20161,106104N/A305N/A
9/30/20161,023151N/A280N/A
6/30/201694174N/A193N/A
3/31/201685849N/A189N/A
12/31/20157547N/A89N/A
9/30/2015634-86N/A61N/A
6/30/201564413N/A81N/A
3/31/2015581-33N/A53N/A
12/31/2014511-48N/A26N/A
9/30/2014485-54N/A-30N/A
6/30/2014372-136N/A-70N/A
3/31/2014374-101N/A-47N/A
12/31/2013355-83N/A9N/A

애널리스트 미래 성장 예측

수입 대 저축률: INCY 의 연간 예상 수익 증가율( 46.5% )이 saving rate( 2.6% 보다 높습니다. ).

수익 vs 시장: INCY 의 연간 수익( 46.5% ) US 시장( 15.4% 보다 빠르게 성장할 것으로 예상됩니다. 15.4% 연간).

고성장 수익: INCY 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: INCY 의 수익(연간 9% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: INCY 의 수익(연간 9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: INCY 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 24.7 %)

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y